Padagis LLC

Company overview. Padagis LLC is a private, private-equity-backed generic pharmaceutical company headquartered at 1251 Lincoln Road, Allegan, Michigan. It was founded in 2004 as the U.S. generic-prescription (Rx) business of Perrigo Company plc and became an independent operating company on July 6, 2021, when Altaris Capital Partners, a healthcare-focused New York private equity firm, acquired it from Perrigo for approximately $1.55 billion. Padagis reports 1,300+ employees across six sites in the U.S. and Israel (manufacturing in Minneapolis, Minnesota and Yeruham, Israel). Because it is private, revenue is not publicly disclosed.

Products / operations. Padagis develops, manufactures, and markets generic Rx and OTC medicines, specializing in "extended topical" dosage forms — creams, ointments, lotions, gels, foams, solutions, and nasal sprays — across categories such as dermatology, hormone therapy, and central nervous system/rescue medicines. Its portfolio spans more than 200 product families and roughly 800 SKUs; its best-known product is a generic naloxone HCl nasal spray for opioid-overdose reversal, which it sells OTC and has recently moved to U.S. production. Padagis also operates a contract development and manufacturing (CDMO) business for topical and nasal drug products. It is an operating company with real products and manufacturing — not a non-practicing entity.

Patent-litigation posture. Padagis appears in the database solely as a defendant: 0 plaintiff cases, 1 defendant case, in the District of Delaware. The suit is Neurelis, Inc. v. Padagis LLC et al. (filed May 8, 2024), a Hatch-Waxman/ANDA action in which Padagis is the generic applicant seeking FDA approval to market a copy of Neurelis's Valtoco® (diazepam nasal spray, 10 mg/spray) before the Orange Book patents expire, via Paragraph IV certifications. Delaware is the customary venue for such cases rather than a plaintiff-friendly outlier.

Notable context. Related public filings show Padagis also filed inter partes review petitions (e.g., IPR2025-00464/465/466) challenging the Valtoco patents, and that its subsidiaries (Padagis US LLC, Padagis Israel) have engaged in prior Hatch-Waxman patent litigation, including counterclaims in Delaware. The company's litigation activity reflects its core strategy: first-to-file generic launches that challenge branded pharmaceutical patents.